Fred Aslan, Artiva Biotherapeutics CEO
Artiva boasts early NK cell therapy results, giving lifeline to partner Affimed
Artiva Biotherapeutics reported early data on its off-the-shelf NK cell therapy in combination with rituximab, suggesting the combo could shrink tumors in non-Hodgkin lymphoma patients who have already tried many other cancer therapies.
Four of six patients who received the combo therapy of AB-101 and rituximab saw their tumors shrink, and three of those six saw signs of cancer go away completely, according to an ASCO abstract released Thursday evening. Three of the patients who responded to treatment have had ongoing responses of five, seven and nine months.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters